Back to search results

Secondary Cytoreductive Surgery and HIPEC for Recurrent Mucinous Ovarian Cancer

This study is looking at a treatment for women with recurrent mucinous ovarian cancer. It combines two approaches: secondary cytoreductive surgery (an operation to remove as much tumor as possible) and hyperthermic intraperitoneal chemotherapy (HIPEC), which involves heating chemotherapy drugs and delivering them directly into the abdomen. The main goal is to see how long patients live without their cancer growing or spreading after this treatment. Researchers will also look at overall survival, side effects, and quality of life. You may be able to join if you are 18 or older, have recurrent mucinous ovarian cancer, and meet certain health requirements. This study plans to enroll 30 participants.

Study design
This is an interventional study planning to enroll 30 participants. It is not specified if it is randomized or blinded.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for an average of 6 years after treatment completion to measure progression-free survival.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05123807

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Recruiting
PHASE2Ages 18+InterventionalTreatment
M.D. Anderson Cancer Center
~30 participants
Updated 2026-04-16 on ClinicalTrials.gov
What's tested:Cytoreductive surgery

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancer
Measured over through study completion, an average of 6 years (patients will be followed for 6 years after treatment completion

Conditions

Ovarian Cancer

Explore related trials

Malignant Ovarian Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Aaron Shafer, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Aaron Shafer, MD
[email protected]
832-885-6133
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients must have histologically or cytologically confirmed recurrent primary mucinous ovarian cancer
Age ≥18 years
ECOG performance status ≤ 2
Prior to surgery, patients must have adequate organ and marrow function as defined below (within 30 days of registration):
Patients must be \> 2 weeks from prior chemotherapy or radiation therapy, except for bevacizumab treatment which requires \>6 weeks
Ability to understand and the willingness to sign a written informed consent document (either directly or via a legally authorized representative)

Exclusion

Patients who are receiving concurrent investigational therapy or who have received investigational therapy within 30 days of HIPEC (investigational therapy is defined as treatment for which there is currently no regulatory authority approved indication)
Patients with mucinous tumors with pathologic confirmation of a non-gynecologic site of origin
Patients with known active CNS metastases
Patients with known hypersensitivity to any of the components of cisplatin
Patients with a prior or concurrent malignancy who natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.
Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
Women who are pregnant or nursing women
Patients with peripheral neuropathy ≥ grade 2
History of allogenic transplant
History of prior HIPEC or intraperitoneal chemotherapy
Known bulky extra-abdominopelvic disease
Patients with hearing impairment/tinnitus ≥ grade 2

What this trial measures

  • To estimate progression-free survival (PFS) after secondary cytoreductive surgery and HIPEC for women with recurrent primary mucinous ovarian cancerthrough study completion, an average of 6 years (patients will be followed for 6 years after treatment completion